Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Interleukin 17a antibody (Interleukin 17A) Primary Antibody

IL17A Reactivity: Human BR, ELISA, FACS, IP, WB Host: CHO Cells Monoclonal Secukinumab unconjugated
Catalog No. ABIN6730994
$360.00
Plus shipping costs $45.00
100 μL
local_shipping Shipping to: United States
Delivery in 7 to 8 Business Days
  • Target
    Interleukin 17a (IL17A)
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 109
    • 49
    • 20
    • 7
    • 5
    • 5
    • 4
    • 3
    • 3
    • 3
    • 3
    Human
    Host
    • 76
    • 35
    • 20
    • 18
    • 3
    CHO Cells
    Clonality
    • 96
    • 56
    Monoclonal
    Conjugate
    • 73
    • 25
    • 16
    • 11
    • 9
    • 7
    • 5
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This Interleukin 17a antibody is un-conjugated
    Application
    • 98
    • 87
    • 35
    • 16
    • 11
    • 11
    • 10
    • 8
    • 6
    • 6
    • 5
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
    Purpose
    Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A).
    Specificity
    "Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A)."
    Characteristics
    "This is a therapeutic antibody derived from Cosentyx and designed for research purposes. Secukinumab, the active ingredient of Cosentyx, is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A)."Secukinumab is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). Secukinumab works by targeting IL-17A and inhibiting its interaction with the IL-17 receptor, which is expressed on various cell types including keratinocytes. As a result, secukinumab inhibits the release of proinflammatory cytokines, chemokines and mediators of tissue damage and reduces IL-17A-mediated contributions to autoimmune and inflammatory diseases. Clinically relevant levels of secukinumab reach the skin and reduce local inflammatory markers. As a direct consequence treatment with secukinumab reduces erythema, induration and desquamation present in plaque psoriasis lesions.
    IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. IL-17A plays a key role in the pathogenesis of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis and is up-regulated in lesional skin in contrast to non-lesional skin of plaque psoriasis patients and in synovial tissue of psoriatic arthritis patients. The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis.
    Purification
    The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml.  (original drug Cosentyx 150 was diluted 1:150)
    Sterility
    Sterile
    Clone
    Secukinumab
    Isotype
    IgG1 kappa
  • Application Notes
    Optimal dilution for a specific application should be determined by user
    Comment

    Secukinumab is a recombinant fully human monoclonal antibody selective for interleukin-17A. Secukinumab is of the IgG1/κ-class produced in Chinese Hamster Ovary (CHO) cells

    Protocol
    Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    The dilutant is sterile PBS pH 7.4. No preservatives added
    Preservative
    Without preservative
    Handling Advice
    open only under sterile conditions
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
    Expiry Date
    36 months
  • Target
    Interleukin 17a (IL17A)
    Alternative Name
    IL 17A (IL17A Antibody Abstract)
    Synonyms
    CTLA8, IL-17, IL-17A, IL17, Ctla-8, Ctla8, Il17, ChIL-17, IL-17F, IL17A, CTLA-8, interleukin 17A, IL17A, Il17a
    Background
    Synonyms: CTLA8, IL-17, IL-17A, IL17, Ctla-8, Ctla8, Il17, ChIL-17, IL-17F, IL17A, CTLA-8
    Molecular Weight
    18 kDa
    Gene ID
    3605
    NCBI Accession
    NM_002190
    UniProt
    Q16552
You are here:
help Support